Within the low-PSA cohort, prostate cancer patients and those with BPH exhibited mean PSA levels of 6.97 ± 1.56 ng/mL and 6.67 ± 1.56 ng/ml respectively, demonstrating no statistically significant difference. Here, KLK3 is linked to benign prostatic hyperplasia.